Bharat Biotech, Sydney ID announce MoU to advance vaccine research initiative

"Mutually, we are excited about the new opportunities to strengthen our shared vision, leverage the prowess of education, and research capabilities to help build a healthier universe and improve people's lives by developing safer vaccine platforms. Most importantly, build the talent of young scientists with a passion to innovate," he said.

Professor Jamie Triccas, the deputy director at Sydney ID said, "Positioning Sydney ID on a global scale to drive innovation and highlight our expertise in the development of new vaccines and biotherapeutics is paramount."

"The reputational and societal impacts of developing novel vaccines to eradicate human and animal diseases that are safe, affordable, and effective cannot be overstated. Together with Bharat Biotech International Ltd, we aim to make a lasting impact on global health," he said.

Vaccines are the most effective and cost-effective way to protect billions of people worldwide, with vaccine development potentially transforming health by removing the burden of life-threatening infectious diseases from the population, Triccas said.

India's capabilities in manufacturing vaccines came to the fore during the COVID-19 pandemic where companies such as Bharat Biotech were able to provide vaccines that met over 60% of the world's demand and supplied over 2.4 billion doses of COVID-19 vaccines, the statement said.